ADC Therapeutics Announces Abstracts Accepted for Presentation at the American Association for Cancer Research Annual Meeting 2025

Core Insights - ADC Therapeutics is set to present preclinical data on its exatecan-based antibody-drug conjugates (ADCs) targeting Claudin-6, PSMA, and ASCT2 at the upcoming AACR Annual Meeting 2025, highlighting its commitment to advancing targeted cancer treatments [1][2][3] Company Overview - ADC Therapeutics is a commercial-stage global leader in the field of antibody-drug conjugates (ADCs), focusing on transforming treatment paradigms for patients with hematologic malignancies and solid tumors [3][4] - The company is based in Lausanne, Switzerland, with operations in London and New Jersey [5] Upcoming Presentations - The oral presentation will focus on ADCT-242, a novel exatecan-based ADC targeting Claudin-6, in ovarian and non-small lung cancer models, scheduled for April 27, 2025 [2] - Poster presentations will include: - ADCT-241, targeting PSMA for prostate cancer, on April 30, 2025 [2] - HuB14-VA-PL2202, targeting ASCT2, on April 28, 2025 [2] Product Development - ADC Therapeutics' CD19-directed ADC ZYNLONTA has received accelerated approval from the FDA and conditional approval from the European Commission for treating relapsed or refractory diffuse large B-cell lymphoma [4]